Clauser Steven B
Outcomes Research Branch, National Cancer Institute, 6130 Executive Boulevard, MSC 7344, EPN Room 4005, Bethesda, MD 20892-7344, USA.
J Natl Cancer Inst Monogr. 2004(33):142-54. doi: 10.1093/jncimonographs/lgh020.
The use of performance measurement to inform macro-level studies of cancer control and quality of care is receiving increasing interest at the state, national, and international level. This article describes the use of these measures to inform health policy and monitor cancer disparities and disease burden. Applications are discussed in clinical and provider-reported outcomes such as cancer incidence, mortality and survival, and outcome-linked processes of care, and patient-reported outcomes such as health-related quality of life and patient satisfaction/experience with care. The use of economic measures to monitor and evaluate the burden of illness is also discussed. The growing demand for surveillance capability coupled with the need to expand both the quality and breadth of available measure sets, suggests that there is a need to supplement traditional clinical and provider-reported process and outcomes measures with patient-reported outcomes measures such as health-related quality of life and patient satisfaction and experience with care. In addition, there is also a need to broaden and standardize outcome-linked process-of-care measures to improve the ability to measure and monitor incremental progress in improving cancer care. Finally, better measures of indirect costs of cancer care, such as loss productivity and caregiver burden among the aged, would improve national estimates of the cost of illness associated with cancer.
利用绩效评估为癌症控制和医疗质量的宏观层面研究提供信息,在州、国家和国际层面正受到越来越多的关注。本文描述了利用这些评估来为卫生政策提供信息以及监测癌症差异和疾病负担。文中讨论了这些评估在临床和提供者报告的结果(如癌症发病率、死亡率和生存率以及与结果相关的护理过程)以及患者报告的结果(如与健康相关的生活质量和患者对护理的满意度/体验)中的应用。还讨论了利用经济评估来监测和评估疾病负担。对监测能力的需求不断增长,同时需要扩大现有评估集的质量和广度,这表明有必要用患者报告的结果评估(如与健康相关的生活质量以及患者对护理的满意度和体验)来补充传统的临床和提供者报告的过程及结果评估。此外,还需要拓宽和规范与结果相关的护理过程评估,以提高衡量和监测改善癌症护理方面渐进进展的能力。最后,更好地衡量癌症护理的间接成本,如老年人的生产力损失和护理者负担,将改善国家对与癌症相关的疾病成本的估计。